Samsung Bioepis and Sandoz are starting a global license, development, and commercialization agreement for up to five biosimilar candidates. These candidates, developed by Samsung Bioepis, include SB36, currently in pre-clinical development, referencing Takeda Pharmaceuticals’ Entyvio (vedolizumab). Entyvio’s indications are for the treatment of adult patients with Crohn’s disease, ulcerative colitis, and pouchitis. In this agreement, Samsung Bioepis will take responsibility for developmen...